297 related articles for article (PubMed ID: 34073710)
21. Effect of cannabidiol on muscarinic neurotransmission in the pre-frontal cortex and hippocampus of the poly I:C rat model of schizophrenia.
Jimenez Naranjo C; Osborne AL; Weston-Green K
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109640. PubMed ID: 31108177
[TBL] [Abstract][Full Text] [Related]
22. Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study.
Gemperle AY; Enz A; Pozza MF; Lüthi A; Olpe HR
Neuroscience; 2003; 117(3):681-95. PubMed ID: 12617972
[TBL] [Abstract][Full Text] [Related]
23. Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.
Horska K; Kotolova H; Karpisek M; Babinska Z; Hammer T; Prochazka J; Stark T; Micale V; Ruda-Kucerova J
Toxicol Appl Pharmacol; 2020 Nov; 406():115214. PubMed ID: 32866524
[TBL] [Abstract][Full Text] [Related]
24. Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.
Breuer A; Haj CG; Fogaça MV; Gomes FV; Silva NR; Pedrazzi JF; Del Bel EA; Hallak JC; Crippa JA; Zuardi AW; Mechoulam R; Guimarães FS
PLoS One; 2016; 11(7):e0158779. PubMed ID: 27416026
[TBL] [Abstract][Full Text] [Related]
25. Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol.
Le Pen G; Jay TM; Krebs MO
J Psychopharmacol; 2011 Jun; 25(6):822-35. PubMed ID: 21088043
[TBL] [Abstract][Full Text] [Related]
26. Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
Takahashi K; Nakagawasai O; Sakuma W; Nemoto W; Odaira T; Lin JR; Onogi H; Srivastava LK; Tan-No K
Neuropharmacology; 2019 May; 150():1-14. PubMed ID: 30831160
[TBL] [Abstract][Full Text] [Related]
27. Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.
Hudson R; Renard J; Norris C; Rushlow WJ; Laviolette SR
J Neurosci; 2019 Oct; 39(44):8762-8777. PubMed ID: 31570536
[TBL] [Abstract][Full Text] [Related]
28. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.
Gomes FV; Llorente R; Del Bel EA; Viveros MP; López-Gallardo M; Guimarães FS
Schizophr Res; 2015 May; 164(1-3):155-63. PubMed ID: 25680767
[TBL] [Abstract][Full Text] [Related]
29. Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia.
Penschuck S; Flagstad P; Didriksen M; Leist M; Michael-Titus AT
Eur J Neurosci; 2006 Jan; 23(1):279-84. PubMed ID: 16420437
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Effects of Iloperidone on Cerebral Serotonin and Adrenoceptor Subtypes.
Choi YK; Tarazi FI
J Mol Neurosci; 2018 Sep; 66(1):59-67. PubMed ID: 30091081
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P
Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Treatment with Atypical Antipsychotic Iloperidone Modulates Cytochrome P450 2D (CYP2D) Expression and Activity in the Liver and Brain via Different Mechanisms.
Danek PJ; Daniel WA
Cells; 2021 Dec; 10(12):. PubMed ID: 34943983
[No Abstract] [Full Text] [Related]
34. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
[TBL] [Abstract][Full Text] [Related]
35. Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.
Kucera J; Horska K; Hruska P; Kuruczova D; Micale V; Ruda-Kucerova J; Bienertova-Vasku J
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110165. PubMed ID: 33152383
[TBL] [Abstract][Full Text] [Related]
36. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.
Ichikawa J; Li Z; Dai J; Meltzer HY
Brain Res; 2002 Nov; 956(2):349-57. PubMed ID: 12445705
[TBL] [Abstract][Full Text] [Related]
37. Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic Transmission in the Mesolimbic System.
Norris C; Loureiro M; Kramar C; Zunder J; Renard J; Rushlow W; Laviolette SR
Neuropsychopharmacology; 2016 Nov; 41(12):2839-2850. PubMed ID: 27296152
[TBL] [Abstract][Full Text] [Related]
38. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
O'Neill A; Wilson R; Blest-Hopley G; Annibale L; Colizzi M; Brammer M; Giampietro V; Bhattacharyya S
Psychol Med; 2021 Mar; 51(4):596-606. PubMed ID: 31994476
[TBL] [Abstract][Full Text] [Related]
39. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.
Sonego AB; Prado DS; Vale GT; Sepulveda-Diaz JE; Cunha TM; Tirapelli CR; Del Bel EA; Raisman-Vozari R; Guimarães FS
Brain Behav Immun; 2018 Nov; 74():241-251. PubMed ID: 30217539
[TBL] [Abstract][Full Text] [Related]
40. Iloperidone, asenapine and lurasidone: a primer on their current status.
Tarazi FI; Stahl SM
Expert Opin Pharmacother; 2012 Sep; 13(13):1911-22. PubMed ID: 22849428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
